| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
4.34(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
773,642 |
| 52
Week Range: |
$23.21 - $33.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 581 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
35,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
10,417 |
15,666 |
21,104 |
96,962 |
| Total Sell Value |
$292,740 |
$454,291 |
$626,511 |
$2,911,362 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
3 |
5 |
8 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mitchell Paul J |
Director |
• • – |
2017-11-01 |
4 |
AS |
$49.16 |
$49,160 |
D/D |
(1,000) |
8,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-11-01 |
4 |
OE |
$11.44 |
$11,440 |
D/D |
1,000 |
9,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-10-02 |
4 |
AS |
$50.64 |
$75,960 |
D/D |
(1,500) |
8,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-10-02 |
4 |
OE |
$11.44 |
$17,160 |
D/D |
1,500 |
9,500 |
|
- |
|
| Biberstein Kathryn L |
EVP/CAO/CCO Alks Inc; Sec ALKS |
• • – |
2017-09-15 |
4 |
D |
$52.22 |
$89,714 |
D/D |
(1,718) |
60,976 |
|
- |
|
| Biberstein Kathryn L |
EVP/CAO/CCO Alks Inc; Sec ALKS |
• • – |
2017-09-15 |
4 |
OE |
$11.74 |
$89,774 |
D/D |
5,805 |
61,589 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2017-09-15 |
4 |
OE |
$14.13 |
$3,533 |
D/D |
250 |
31,407 |
|
- |
|
| Bloom Floyd E |
Director |
• • – |
2017-09-12 |
4 |
OE |
$11.44 |
$228,800 |
I/I |
20,000 |
20,000 |
|
- |
|
| Biberstein Kathryn L |
EVP/CAO/CCO Alks Inc; Sec ALKS |
• • – |
2017-09-11 |
4 |
AS |
$51.18 |
$695,817 |
D/D |
(13,566) |
56,889 |
|
- |
|
| Biberstein Kathryn L |
EVP/CAO/CCO Alks Inc; Sec ALKS |
• • – |
2017-09-11 |
4 |
OE |
$14.13 |
$191,688 |
D/D |
13,566 |
70,455 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-08-01 |
4 |
AS |
$54.91 |
$82,365 |
D/D |
(1,500) |
8,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-08-01 |
4 |
OE |
$11.44 |
$17,160 |
D/D |
1,500 |
9,500 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-07-03 |
4 |
AS |
$58.11 |
$87,165 |
D/D |
(1,500) |
8,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-07-03 |
4 |
OE |
$11.44 |
$17,160 |
D/D |
1,500 |
9,500 |
|
- |
|
| Frates James M |
SVP, Alks Inc; CFO ALKS |
• • – |
2017-06-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
127,477 |
|
- |
|
| Stejbach Mark |
SVP/Chief Comm Off, Alks Inc |
• • – |
2017-06-08 |
4 |
AS |
$60.34 |
$603,352 |
D/D |
(10,000) |
44,013 |
|
- |
|
| Stejbach Mark |
SVP/Chief Comm Off, Alks Inc |
• • – |
2017-06-08 |
4 |
OE |
$17.30 |
$173,000 |
D/D |
10,000 |
54,013 |
|
- |
|
| Cooke Shane |
President, Alkermes plc |
• • – |
2017-06-08 |
4 |
AS |
$60.33 |
$603,333 |
D/D |
(10,000) |
74,708 |
|
- |
|
| Cooke Shane |
President, Alkermes plc |
• • – |
2017-06-08 |
4 |
OE |
$16.55 |
$165,500 |
D/D |
10,000 |
84,708 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-06-01 |
4 |
AS |
$57.49 |
$86,235 |
D/D |
(1,500) |
8,000 |
|
- |
|
| Mitchell Paul J |
Director |
• • – |
2017-06-01 |
4 |
OE |
$11.44 |
$17,160 |
D/D |
1,500 |
9,500 |
|
- |
|
| Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
• • – |
2017-05-28 |
4 |
D |
$57.70 |
$32,774 |
D/D |
(568) |
27,595 |
|
- |
|
| Brown Iain Michael |
SVP Finance & CAO, Alks Inc. |
• • – |
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
28,163 |
|
- |
|
| Ehrich Elliot |
EVP, R&D & CMO, Alkermes, Inc. |
• • – |
2017-05-28 |
4 |
D |
$57.70 |
$101,841 |
D/D |
(1,765) |
57,056 |
|
- |
|
| Ehrich Elliot |
EVP, R&D & CMO, Alkermes, Inc. |
• • – |
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,750 |
58,821 |
|
- |
|
2018 Records found
|
|
Page 29 of 81 |
|
|
0.41 (1.68%) 
